ATPsensitive potassium (KATP) channels reside in the plasmamembrane of manyexcitable cells such as pancreatic (3-cells, heart, skeletal muscle and brain, where they link cellular metabolic energy to membraneelectrical activity. They are composed of two subunits, K+ion selective pore (Kir) and sulfonylurea receptor (SUR). In addition to the central role of pancreatic p-cell KATPchannels in glucose-mediated insulin secretion, several lines of evidence support the hypothesis that KATPchannels modulate glucose transport in the insulin target tissues. Inhibition of KATP channels by glibenclamide or gliclazide or an increase in intracellular ATPduring hyperglycemia (glucose effect) or exercise facilitates glucose utilization, while activation of the channels by potassium channel openers, hypothermia (cardiac surgery), or ischemic damage (myocardial and brain infarction) reduces glucose uptake induced by insulin or hyperglycemia. Because insulin action has been known to depend on the energy level of the target cells, KATPchannel mayfunction as an effector in this respect. It is now evident that long chain acyl-CoA esters, metabolically active forms of fatty acids, are the most potent and physiologically important activator of KATPchannels. Thus, I suppose that the sustained activation of KATPchannels by long chain fatty acyl-CoA seems to be a missing link between lipotoxicity and insulin resistance in obesity and type 2 diabetes mellitus. (Internal Medicine 41 : 84-90, 2002) 
Introduction
Potassium (K+) channels play a key role in cellular physiology by regulating the efflux of K+ ion. They are the most diverse group of ion channel proteins; more than 30 K+channel genes have been identified, and an individual K+ channel was characterized to have a unique physiological regulation by adenosine triphosphate (ATP), voltage or Ca2+ ion, etc. ATP-sensitive potassium (KATP)channels are regulated by intracellular ATPand Mg-adenosine diphosphate (ADP) concentrations or the ATP/ADPratio. For example, an increase in the ATP/ADP ratio closes KATPchannels, whereas a decrease in the ratio opens them. KATPchannels are composed of the physical association of four inwardly rectifying K+ channel (Kir6.2) subunits with four sulfonylurea receptor (SUR) subunits ( 1-3). Kir6.2 serves as a K+ion selective pore. SURis a regulatory subunit that modulates the channel gating property, and acts as the target for sulfonylureas (SUs), K+ channel openers and Mg-nucleotide, all modulate Kir6.2 subunit sensitivity to ATP (4) (5) (6) (7) (8) . It is currently believed that Kir6.2/SUR1 forms the pancreatic J3-cell and the hypothalamic glucose-responsive neuron KATPchannel, Kir6.2/SUR2A forms the cardiac and skeletal muscle KATP channel, Kir6.2/SUR2B forms the smooth muscle KATPchannel, and Kir6. 1/SUR2Bforms the vascular smooth muscle counterpart (9). KATPchannels are found in a variety of excitable cells, wherethey serve to couple the metabolic state of the cell to its electrical activity (10). Thus, they primarily set the resting membrane potential. Its closure elicits membrane depolarization, activation of voltage-dependent Ca2+ channels, and a rise in Ca2+ influx that regulates many cellular functions including insulin exocytosis from p-cells, vascular contraction, and neurotransmitter release from nerve terminals. Conversely, its opening elicits membranehyperpolarization which brings the cells to a resting state that allows the minimalenergy requirement, thereby protecting cells against damage from energy depletion as seen in cardiac and brain ischemia (ll, 12). Here I review the previous studies including ours on the role of extrapancreatic KATPchannels in glucose homeostasis, and I propose the hypothesis that a sustained opening of KATP channels in insulin target tissues may be a unifying adaptive mechanism for insulin resistance in obesity and type 2 diabe- to yield two patterns of response; insulin-independent stimulation of glucose uptake (1 3, 14) and potentiation of insulin-stimulated glucose uptake with no effect on the basal rate (15, 16).
Probably it depends on the tissue difference in the KATPchannel sensitivity or selectivity to SUs: for example, KATPchannels in skeletal muscle are approximately 30 to 300-fold less sensitive to inhibition by glibenclamide compared with those in pancreatic p-cells (17, 18).
Tolbutamide stimulated glucose oxidation in the isolated perfused rat heart, and the contribution of glucose oxidation to overall ATPproduction rose with increasing concentration of tolbutamide from 8% in the absence of drug to 30% (19). Infusion of the therapeutic level of tolbutamide (7x10^M) acutely stimulated glucose uptake in the perfused rat hindlimb (20 that KATPchannels in skeletal muscle might be involved in insulin-stimulated whole-body glucose disposal. Recently, SUR1 knockout mice (SURl"7") have also been generated, p-cells from SUR1'" mice showed similar electrophysiological behaviors to those found in Kir6.2 /" mice. Intraperitoneal injection of glucose caused no insulin response in mutant mice, but they maintained a near normoglycemic state, suggesting increased whole-body insulin sensitivity (24).
In humans, an oc2-adrenergic blocker midaglizole, which was later found to have KATPchannel blocking activity in the imidazoline moiety of this compound(25), was shown to promote not only insulin secretion but also glucose disposal determined by a euglycemic hyperinsulinemic clamp method in NIDDM patients (26). Thus, the inhibition of KATPchannels in peripheral tissues (primarily skeletal muscle) likely improves a wholebody insulin sensitivity in humans. In addition, Hansen et al (27) searched for mutations in the Kir6.2 gene in 346 young healthy subjects. The amino acid polymorphisms were associated neither with altered insulin secretion after intravenous administration of glucose or tolbutamide nor with altered glucose effectiveness by the minimal model analysis. However, carriers of the maximal load of amino acid variants had on average a 62% higher insulin sensitivity index (p=0.006) compared with noncarriers. They suggested that a combination of commonKir6.2 amino acid variants maycontribute to the genetic background behind the large variation of the insulin sensitivity in the general population.
Wehave also addressed this issue at both the clinical and cellular levels. Our initial interest was the following observation that anti-anginal drug nicorandil, a KATPchannel opener, was found to impair glycemic control in type 2 diabetic patients without interfering with insulin secretion (28). A 7-day trial of nicorandil (15 mg/day) in three healthy male volunteers caused on average a 37.3% (26.9^4-2.9) reduction of glucose infusion rate estimated by a euglycemic hyperinsulinemic clamp technique (Fig. 1 ). To avoid a potential hemodynamic effect of nicorandil, a series of in vitro studies were performed (29). We examined the effects of KATPchannel openers (PCO-400 and nicorandil) alone or in combination with channel blockers (glibenclamide and gliclazide) on insulin-or high glucose concentration-stimulated glucose transport in cultured human skeletal muscle cells. PCO-400 alone reduced the basal glucose uptake in the absence of insulin. PCO-400 and nicorandil dose-dependently inhibited insulin-stimulated glucose uptake, and their inhibition was reversed by the pretreatment with glibenclamide or gliclazide in dose-dependent manner ( Fig. 2) . PCO-400 inhibited 25 mMglucose-facilitated glucose transport in the absence of insulin, and this effect was also antagonized by both SUs (Fig. 3) . Wehave further shown that a phorbol ester (PMA), an activator of PKC, dose-dependently reversed the PCO-400 inhibition of insulin-stimulated glucose uptake; this finding was consistent with the previous observation in rat aortic rings (30), but not with other reports in insulinoma cells (31, 32). In our experiments, membraneassociated PKCactivity showed no change following incuba- pathway induced by insulin and high glucose is believed to be separate (33) , KATPchannel seems to be a commoneffector responsible for both processes.
Apart from glucose metabolism, KATPchannels have been shown to elicit some effects on lipid metabolism. Diazoxide alone fails to exert any effect on fatty acid synthase (FAS) activity in cultured 3T3-L1 adipocytes, but diazoxide completely inhibits insulin-induced activation of FAS activity (34) . Glibenclamide stimulates FASactivity, which is inhibited by diazoxide and calcium channel antagonists (35) . Therefore, it is interesting to note that there is a cross-talk between the insulin signaling pathway and KATPchannel activity in adipocytes aswell.
Role of Hexosamine Biosynthetic Pathway in Glucose Toxicity
Chronic hyperglycemia has been claimed to cause insulin resistance. Amongthe hypotheses, an accelerated hexosamine biosynthetic pathway has been highlighted as a mechanism for glucose toxicity. Originally, Marshall et al (36) suggested that an increased production of UDP-N-acetyl hexosamine, an ultimate product of this pathway, maybe the mechanism by which hyperglycemia leads to insulin resistance. Their conclusion was based on the following evidence: 1) glucose and insulin per se are not sufficient to produce insulin resistance in primary adipocytes, but the presence of glutamine is essential, 2) de- Figure 2 . Effect of glibenclamide (30-100 jjM) or glidazide (300-3,000 |iM) on PCO-400-induced inhibition of insulin-stimulated 2-deoxy-glucose uptake. In order to prevent cell damaging by concomitant incubation with high concentrations of glibenclamide or gliclazide and PCO-400 in the protein-free uptake solution, the cells were pretreated with SU drugs for 18 hours in the protein-containing differentiation medium, then subjected to incubation with PCO-400for 90 minutes in the uptake solution. 2-DG uptake for 15 minutes was measured using 3H-2-DG. Non-specific uptake was determined in parallel incubation by inhibiting transporter-mediated uptake with 25 |LiM cytochala- Effect of glibenclamide (30-100 uM) or glidazide (300-3,000 uM) on PCO-400-induced inhibition of high glucose (25 mM)-facilitated glucose uptake. The cells were first incubated with SU drugs, followed by incubation with PCO-400 for 90 minutes as described in the note to Fig. 2 . Glucose uptake for 30 minutes was measured using 3-O-methyl-3H-glucose. Mean±SE sensitization to insulin can be prevented by inhibitors of the rate-limiting enzyme of this pathway, glutamine: fructosesphosphate amidotransferase (GFAT), and 3) glucosamine, entering the pathway downstream of the rate-limiting step, is 40-times stronger than glucose in mediating desensitization of insulin-stimulated glucose transport. Their results were confirmed by many subsequent studies, in vitro, including studies in primary rat adipocytes (37), 3T3-L1 adipocytes (38) , and isolated skeletal muscle (39) and, in vivo, by measuring whole-body glucose disposal after glucosamine clamping (40) (41) (42) . Similarly, in transgenic mice overexpressing GFATspecifically in muscle and fat, insulin-stimulated glucose uptake was shown to decrease by half (43) . Recently, Hresko et al (44) made the novel observations that allow an alternative explanation for the pathogenesis of insulin resistance induced by glucosamine; 1) insulin desensitization by glucosamine was intimately correlated with the decrease in intracellular ATPcontent rather than the generation of UDP-N-acetyl hexosamine, 2) reduction of intracellular ATPby sodium azide (inhibitor of mitochondrial electron transport) similarly inhibited GLUT4translocation to the plasma membrane, and 3) both the reduction in [ATP]; and the glucosamine-induced insulin resistance were prevented by the addition of an alternative energy substrate inosine. Based upon these observations, they concluded that any desensitization of the insulinstimulated glucose transport in 3T3-L1 adipocytes by glucosamine treatment is due entirely to effects on ATPand not to an increase in intracellular UDP-N-acetyl hexosamine levels.
They argued that even a minor reduction in ATP (10-20%) is capable of causing insulin desensitization. The decrease in
[ATP]j by glucosamine was considered to be due to rapid phosphorylation by hexokinase of newly fluxed glucosamine. Like glucosamine, uridine also inhibited insulin-stimulated glucose uptake in 3T3-L1 adipocytes, because this substrate also consumes high energy phosphates upon conversion to UDP-sugar. The authors suggested that any cellular defect that results in a decreased steady-state level ofATPmay induce a state of insulin resistance. However, the results by Hresko et al (44) are challenged by several studies to date (45) (46) (47) . On the other hand, it has long been known that insulin action depends on the energy levels of the target cells (48) (49) (50) (51) . For example, whenisolated rat epididymal fat cells were incubated with insulin in the presence of uncouplers of oxidative phosphorylation, the resultant decrease in the ATPlevel coincided with a disappearance of the stimulatory effects of insulin on sugar transport (48) . The coupling step between insulin receptors and the glucose transport system, rather than insulin receptor binding and glucose transport itself, was previously shown to have a high activation energy (EA=24 kcal/mol), suggesting an energy requirement for activation (5 1).
Role of Intracellular Long Chain Fatty Acyl-CoA or Triglyceride

Accumulation in Lipotoxicity
Recently, Unger and colleagues have extensively explored the relationship between intracellular triglyceride (TG) accumulation in both skeletal muscle and liver and the cellular response of glucose transport to insulin (52) (53) (54) (55) . They showed a highly significant correlation between insulin resistance and TGcontent in these insulin target tissues. The concomitant elevation of palmitate-derived ceramide in these tissues has been suggested to lead to insulin resistance by inhibiting PKBpathway, which is a major regulator for glycogen synthase activity.
Plasma FFA elevation induced by lipid/heparin infusion during hyperinsulinemic glucose clamps has repeatedly been shown to decrease insulin-dependent whole-body glucose disposal in healthy and diabetic subjects 3-4 hours after the start of lipid infusion (55) (56) (57) (58) (59) (60) , indicating that FFA exerts a relatively acute effect. The ]3CP]P NMRspectrometry studied by Shulman's group revealed that the rate-controlling step in glucose utilization by skeletal muscle under lipid/heparin infusion is at the glucose transport across the plasma membrane (58, 60) . Han et al demonstrated that a high-fat feeding of 4 weeks in rats reduced the insulin-stimulated skeletal muscle glucose uptake by 25-40% associated with neither decreased GLUT4 content nor increased fat oxidation (61) . These findings are against Randle's glucose-fatty acid cycle hypothesis. High-fat feeding might alter glucose transport by changing the lipid composition of the plasma membrane,which mayaffect its fluidity/permeability (62) . This could in turn affect GLUT4 translocation, or the capacity of GLUT4vesicles to bind or fuse with the plasma membrane (62) . In this regard, it was previously reported that long chain polyunsaturated fatty acids (arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid: C20-C22) in muscle membrane phospholipids are inversely related to insulin resistance, whereas linoleic acid and trans fatty acids are positively related to insulin resistance (63) . Onerecent study has shown that acyl-CoA synthase is associated with GLUT4-containing vesicles in adipocytes, and fatty acyl-CoAs play a role in budding and fusion in membranetrafficking (6 1 ). Therefore, the possibility of lipid-induced abnormalities in the glucose transport system should be seriously evaluated (64) .
Recently, there is a growing body of evidence that some FFAs or their metabolically active forms, long chain acyl-CoA esters (LC-CoA), directly activate KATP channels (65, 66) . Larsson et al (67, 68) demonstrated, for the first time, that by using the patch-clamp technique a markedactivation of the KATPchannel of pancreatic p-cells occurs in response to LCCoA.The effect was concentration-dependent within the lower physiological concentration range ( 10 nM-1 |iM), and also chain length-dependent: oleoyl-CoA (C 1 8: l ), palmitoyl-CoA (C 16:0) and myristoyl-CoA (C 14:0) had a stimulatory effect but malonyl-CoA (C3:0) did not (Fig. 4) . On the molar basis, the LCCoAsare estimated to be 100-1000 times more potent than ADPin stimulating channel activity. It was shown that 1 \xM oleoyl-CoA activates the cloned p-cell KATPchannels through an interaction with Kir6.2 subunit, unlike Mg-ADPand diazoxide which interact with SUR1(69). Thus, it seems reasonable to assume that KATPchannels other than the pancreatic p-cell counterpart are similarly sensitive targets for LC-CoA. An increase in intracellular LC-CoAconcentrations following long-term exposure to elevated levels of circulating free fatty acids should enhance the activity of the KATPchannel. In addition, the inhibition of oxidative phosphorylation by an increase in malonyl-CoA secondary to hyperglycemia may partly contribute to the enhancement of intracellular LC-CoAlevels. LCCoAprevents the closure of KATPchannel in insulin target tissues and contributes to the development of insulin desensitization as well as p-cell insensitivity to glucose. If it is proven, the prolonged activation of KATPchannels by LC-CoA seems to be a missing link between lipotoxicity and insulin resistance in obesity and type 2 diabetes mellitus.
Summaryand Conclusions
The pathogenesis of insulin resistance is multietiological. In some physiological and pathophysiological conditions, especially obesity and type 2 diabetes mellitus, insulin resistance seems to link to the activation of KATPchannels in insulin target tissues. KATP channels serve as a sensor of cellular energy metabolism in manyexcitable cells. They might protect the cells when the cells meet the energy shortage (or inversely the cells meet the affluent influx of FFA) by opening the channels, hyperpolarizing plasma membrane, and blocking Ca2+ entry into the cells. Conversely, when the cells need continuous ATPproduction as seen during exercise, KATPchannels close to facilitate substrate transport. It is nowevident that LC-CoA, metabolically active forms of fatty acid, are the most potent and physiologically important regulator of KATPchannels. In obesity and type 2 diabetes, LC-CoAconcentrations in insulin target tissues should be elevated due to increased availability of FFA, and, in part, inhibition of oxidative phosphorylation by malonyl-CoA derived from increased influx of glucose. Similar but moresevere metabolic conditions include starvation, pregnancy, and lipoatrophic diabetes, all known insulin resistant states associated with accelerated lipid catabolism. Exercise raises the intracellular ATPconcentration in contracting muscles, and oppositely, a sedentary state, aging and natural hibernation reduce it.
By use of NMR spectroscopy, it was demonstrated that the rate-controlling step in insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes resides in glucose transport rather than glucose phosphorylation by hexokinase or glycogen synthesis. Our findings that pharmacological manipulation of KATP channels in skeletal muscle cells affects the glucose transport in vitro, supports the hypothesis that KATP channel activity per se modulates glucose transport through unknownmechanism.In this context, it is of interest to note that the activity of the glucose transporter is increased as the phospholipid headgroup which resides at the surface of the lipid bilayer of the membraneis changed to a more negatively charged species (70 
